COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

MDT-1118 Japan DT Study (MDT-1118 Japan)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03884504
Recruitment Status : Active, not recruiting
First Posted : March 21, 2019
Last Update Posted : March 20, 2020
Information provided by (Responsible Party):
Medtronic Cardiac Rhythm and Heart Failure

Brief Summary:
To evaluate the safety and effectiveness of the MDT-1118 VAD in a patient population for destination therapy (long term support) of advanced heart failure. The collected data will be used to support Japan regulatory application in expanding market approval for destination therapy.

Condition or disease Intervention/treatment Phase
Heart Failure Device: Ventricular Assist Device System Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Single Arm Clinical Study to Evaluate the MDT-1118 Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure
Actual Study Start Date : May 1, 2019
Estimated Primary Completion Date : October 30, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Intervention Details:
  • Device: Ventricular Assist Device System
    Ventricular Assist Device System

Primary Outcome Measures :
  1. Success at 12 months with the following definitions of success and failure [ Time Frame: Implant to 12 months ]

    Therapy will be considered a success if, at the end of 12 months in the study:

    1. The subject is alive; and
    2. The subject has not had a stroke of Modified Rankin Score ≥ 4; and
    3. The subject retains the originally implanted device, unless the device was removed due to heart recovery, or the patient is electively transplanted.

    Therapy will be considered a failure if, within the 12 months in the study:

    1. The subject dies; or
    2. The subject has a stroke of Modified Rankin Score ≥ 4; or
    3. The device malfunctions or fails, requiring exchange, explantation, or urgent transplantation.

Secondary Outcome Measures :
  1. Incidence of all adverse events per INTERMACS definition [ Time Frame: Implant to 12 months ]
  2. Incidence of all device malfunctions per INTERMACS definition [ Time Frame: Implant to 12 months ]
  3. Health Status improvement, as measured by KCCQ [ Time Frame: Implant to 12 months ]
  4. Health Status improvement, as measured by EuroQol EQ-5D-5L [ Time Frame: Implant to 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must be ≥20 years of age at consent
  2. In judgment of body size, body surface area (BSA) and anatomy by Investigator, patient can be implanted MDT-1118 VAD.
  3. Patients with advanced heart failure symptoms (Class IIIB or IV) who are: (patient must meet one of the following)

    1. On optimal medical management, including dietary salt restriction and diuretics, for at least 45 out of the last 60 days and are failing to respond; or
    2. In Class III or Class IV heart failure for at least 14 days, and dependent on intra-aortic balloon pump (IABP) for 7 days and/or inotropes for at least 14 days
  4. Left ventricular ejection fraction ≤ 25%
  5. LVAD implant is intended as destination therapy
  6. Must be able to receive the MDT-1118 VAD
  7. Female patients of childbearing potential must agree to use adequate contraceptive precautions (defined as oral contraceptives, intrauterine devices, surgical contraceptives or a combination of condom and spermicide) for the duration of the study
  8. The patient has signed the informed consent form and advance directive
  9. The patient and the family understand that destination therapy is end-of-life medical care.

Exclusion Criteria:

  1. Patients with INTERMACS profile 1
  2. Existence of any ongoing mechanical circulatory support (MCS) other than an intra-aortic balloon pump (IABP)
  3. Prior cardiac transplant
  4. History of confirmed, untreated abdominal/ thoracic aortic aneurysm > 5 cm, or cardiac aneurysm or intraventricular septum rupture
  5. Severe calcification in thoracic aorta
  6. Cardiothoracic surgery within 14 days of implantation
  7. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave changes on the ECG, diagnostic biomarkers, ongoing pain and hemodynamic abnormalities as described in the guidelines published in ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction1
  8. Patients eligible for cardiac transplantation
  9. On ventilator support for > 72 hours within the four days immediately prior to implantation
  10. Pulmonary embolus within 21 days of implantation as documented by computed tomography (CT) scan or magnetic resonance imaging (MRI)
  11. Symptomatic cerebrovascular disease, stroke within 180 days of implantation or > 80% stenosis of carotid or cranial vessels
  12. Patient seems difficult to control device by oneself due to cerebral disorder
  13. History of drug intoxication or alcohol dependence
  14. Uncorrected moderate to severe aortic insufficiency. Correction may include repair or bioprosthesis at the time of implant
  15. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) at the time of screening or right atrial pressure > 20 mmHg on multiple inotropes or right ventricular ejection fraction (RVEF) <15% with clinical signs of severe right heart failure (e.g. Lower extremity edema, ascites or pleural effusions refractory to treatment with diuretics and two inotropic drugs)
  16. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and laboratory testing, including but not limited to, continued positive cultures, elevated temperature and white blood cell (WBC) count, hypotension, tachycardia, generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment
  17. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count < 75,000, INR > 2.0 or PTT > 2.5 times control in the absence of anticoagulation therapy)
  18. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status
  19. Serum creatinine > 3.0 mg/dL within 72 hours of implantation or requiring dialysis or ultrafiltration
  20. Specific liver enzymes [AST (SGOT) and ALT (SGPT] > 3 times upper limit of normal within 72 hours of implantation
  21. A total bilirubin > 3 mg/dL within 72 hours of implantation, or biopsy proven liver cirrhosis or portal hypertension
  22. Patients with a mechanical heart valve
  23. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy
  24. History of severe COPD or severe restrictive lung disease (e.g FEV1 <50%) or severe pulmonary hypertension
  25. Participation in any other study involving investigational drugs or devices
  26. Severe illness, other than heart disease, which would limit survival to < 3 years
  27. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities
  28. Pregnancy
  29. Patient unwilling or unable to comply with study requirements
  30. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of the investigator
  31. Inadequate family/social support
  32. Systemic disease including collagen disease, insulin dependent severe diabetes or irreversible multi-organ failure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03884504

Layout table for location information
University of Tokyo
Tokyo, Japan
Sponsors and Collaborators
Medtronic Cardiac Rhythm and Heart Failure
Layout table for additonal information
Responsible Party: Medtronic Cardiac Rhythm and Heart Failure Identifier: NCT03884504    
Other Study ID Numbers: MDT18052
First Posted: March 21, 2019    Key Record Dates
Last Update Posted: March 20, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medtronic Cardiac Rhythm and Heart Failure:
Advanced Heart Failure
Ventricular Assist Device System
Destination Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases